Essential Thrombocythemia clinical trials at UCLA
3 in progress, 0 open to eligible people
CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
Sorry, in progress, not accepting new patients
Phase 1 Part (Complete): Open-label, sequential dose escalation study of pelabresib in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis. Phase 2 Part: Open-label study of CPI-0610 with and without Ruxolitinib in patients with Myelofibrosis. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
Los Angeles, California and other locations
Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
Sorry, in progress, not accepting new patients
A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
Los Angeles, California and other locations
Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Sorry, in progress, not accepting new patients
The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.
Los Angeles, California and other locations
Our lead scientists for Essential Thrombocythemia research studies include Gary Schiller.
Last updated: